Literature DB >> 20096266

A claudin-4 modulator enhances the mucosal absorption of a biologically active peptide.

Hiroshi Uchida1, Masuo Kondoh, Takeshi Hanada, Azusa Takahashi, Takao Hamakubo, Kiyohito Yagi.   

Abstract

Biologics, such as peptides, proteins and nucleic acids, are emerging pharmaceuticals. Passage across the epithelium is the first step in the absorption of biologics. Tight junctions (TJ) function as seals between adjacent epithelial cells, preventing free movement of solutes across the epithelium. We previously found that modulation of a key TJ component, claudin-4, is a potent method to enhance jejunal absorption when we used dextran as a model drug and the C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE) as a claudin-4 modulator. Here, we investigated whether the claudin-4 modulator enhances jejunal, nasal and pulmonary absorption of a biologics human parathyroid hormone derivative, hPTH(1-34). The claudin-4 modulator enhanced nasal but not jejunal and pulmonary absorption of hPTH(1-34). C-CPE is hydrophobic with low solubility of less than 0.3mg/ml, but deletion of 10 amino acids at the N-terminal of C-CPE increased its solubility by 30-fold. Moreover, the N-terminal truncated C-CPE bound to claudin-4, modulated the TJ-barrier and enhanced jejunal absorption of dextran. The N-terminal-truncated C-CPE also enhanced jejunal and pulmonary absorption of hPTH(1-34). This report is the first to indicate that a claudin-4 modulator may be a promising enhancer of the jejunal, pulmonary and nasal absorption of a peptide drug. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096266     DOI: 10.1016/j.bcp.2010.01.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Development and application of a mouse intestinal loop model to study the in vivo action of Clostridium perfringens enterotoxin.

Authors:  Justin A Caserta; Susan L Robertson; Juliann Saputo; Archana Shrestha; Bruce A McClane; Francisco A Uzal
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

Review 2.  Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Authors:  Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

3.  In-silico design and production of a novel antigenic chimeric Shigella IpaB fused to C-terminal of Clostridium perfringens enterotoxin.

Authors:  Sina Arabshahi; Abdollah Derakhshandeh; Bahar Nayeri Fasaei; Aytak Novinrooz
Journal:  Mol Biol Rep       Date:  2019-08-31       Impact factor: 2.316

4.  Use of Clostridium perfringens Enterotoxin and the Enterotoxin Receptor-Binding Domain (C-CPE) for Cancer Treatment: Opportunities and Challenges.

Authors:  Zhijian Gao; Bruce A McClane
Journal:  J Toxicol       Date:  2011-09-15

Review 5.  On the interaction of Clostridium perfringens enterotoxin with claudins.

Authors:  Anna Veshnyakova; Jonas Protze; Jan Rossa; Ingolf E Blasig; Gerd Krause; Joerg Piontek
Journal:  Toxins (Basel)       Date:  2010-06-08       Impact factor: 4.546

6.  The tight-junction protein claudin-6 induces epithelial differentiation from mouse F9 and embryonic stem cells.

Authors:  Kotaro Sugimoto; Naoki Ichikawa-Tomikawa; Seiro Satohisa; Yushi Akashi; Risa Kanai; Tsuyoshi Saito; Norimasa Sawada; Hideki Chiba
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

7.  Enteroendocrine cells are specifically marked by cell surface expression of claudin-4 in mouse small intestine.

Authors:  Takahiro Nagatake; Harumi Fujita; Nagahiro Minato; Yoko Hamazaki
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

Review 8.  Claudins in intestines: Distribution and functional significance in health and diseases.

Authors:  Zhe Lu; Lei Ding; Qun Lu; Yan-Hua Chen
Journal:  Tissue Barriers       Date:  2013-05-30

9.  Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway.

Authors:  Tsuyoshi Kono; Masuo Kondoh; Daisuke Kyuno; Tatsuya Ito; Yasutoshi Kimura; Masafumi Imamura; Takayuki Kohno; Takumi Konno; Tomohisa Furuhata; Norimasa Sawada; Koichi Hirata; Takashi Kojima
Journal:  Pharmacol Res Perspect       Date:  2015-12-20

10.  Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.

Authors:  Yosuke Hashimoto; Yumi Kawahigashi; Tomoyuki Hata; Xiangru Li; Akihiro Watari; Minoru Tada; Akiko Ishii-Watabe; Yoshiaki Okada; Takefumi Doi; Masayoshi Fukasawa; Hiroki Kuniyasu; Kiyohito Yagi; Masuo Kondoh
Journal:  Pharmacol Res Perspect       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.